• A review and analysis of the patient's pathology report relating to TNM staging ("Tumor Node Metastasis"); review of the patient's medical history, lifestyle and risk factors, family history, and current condition.
• Discussion of how co-morbid conditions or diseases could affect cancer treatment.
• Review of symptoms prior to presentation.
• Referrals, at the patient’s request, to medical oncologists, radiation oncologists, surgical oncologists, radiologists, interventional radiologists, neurosurgeons and neuro-oncologists, pain management specialists, and additional specialists (e.g., pulmonologists, nephrologists, endocrinologists, gastroenterologists, dermatologists) relevant to the patient's ongoing care.
• Referrals to support groups that may be of assistance in handling the emotional impact that cancer has on the patient and the patient's family.
• Referrals to cancer-specific organizations that may be of assistance in addressing insurance issues or employment termination issues (because of diagnosis or disclosure of metastatic disease).
• Review of the nature/amelioration of specific side effects from chemotherapy, targeted drugs, immunotherapies, or other anticancer therapies.
• Discussion of the interaction of diet and anticancer drugs based on recent studies.
• Discussion of the reasons that supplements or complementary and alternative medicinal “CAM”) products may be prohibited in a clinical trial setting.
• Delineation of the symptoms about which the patient should alert his/her oncologist.
• Discussion of relevant imaging.

• Discussion of pain management issues and treatment options that can be addressed with the patient's oncology team.
• Explanation of the recommendations given or not given by the patient's physicians; assistance in answering the patient's questions which remain either after or between appointments with the medical team.
• Review of the relevant radiation therapy/interventional radiology options which the patient, in turn, may discuss with his/her medical oncology team.
• Review and discussion of the patient’s genomics/next-generation sequencing studies, proteomics studies, and immune cell studies to better understand the molecular characterization and resistance mechanisms of the patient’s cancer.
• Analysis of relevant cancer clinical trials options as well as the nature and purpose of clinical trials using Remission Coach®.
• Review of relevant cancer-specific drugs in the anticancer pipeline.
• Review of Cyber Knife, Gamma Knife, and Whole Brain Radiation Therapy (WBRT), and craniotomy, when necessary. 
  
• Discussion of LMD or leptomeningeal disease, when that is diagnosed.
• Discussion of anticancer drugs which cross the blood-brain barrier if the patient has been diagnosed with brain metastasis.
  
• Review of the available options regarding the possibility of the oncology team securing pre-approval access via a Single-Patient Clinical Protocol /compassionate use / "Right to Try" request for an appropriate anticancer drug that the patient is unable to access in a clinical trial.
• Exploration of options that might defray airfare or hotel expenses for the patient traveling to a clinical trial.

ICAN is currently working on The Bryan K. Guidizi Lung Cancer Program. We are working to put together a Family and Friends Advisory Council for the The Bryan K. Guidizi Lung Cancer Program. If interested, please email us at Bryan.Guidizi.Program@askican.org.

If you would like to become involved as a donor and supporter or a member of our Cancer Research Literature team as a Research Team Leader (medical school students, physicians, nurses, and post-docs only please), you may reach us at Bryan.Guidizi.Program@askican.org.

Federal Tax I.D.: EIN 86-0818253